Key result
Statins require tailored strategies in CKD due to altered lipid metabolism and variable safety profiles.
Why the study?
Do statins improve clinical outcomes in patients with chronic kidney disease?
Do statins improve clinical outcomes in patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
This review discusses the unique challenges of managing dyslipidemia in CKD, focusing on statin efficacy, safety, and guideline recommendations tailored to renal function.
Statins are effective in improving outcomes in the general population. However, in patients with chronic kidney disease (CKD), clinical outcomes and therapeutic approaches require careful interpretation from multiple perspectives. Managing dyslipidemia in CKD presents unique challenges requiring a comprehensive understanding of alterations in lipid metabolism in renal dysfunction. This review explored the key factors influencing statin efficacy, safety, and guideline recommendations in the CKD population, with a focus on lipid-lowering strategies tailored to renal function.
No takes yet. Share an insight, caveat, or question.
Jihyun Yang (2025) conducted a review in Chronic kidney disease. Statins was evaluated. Statins require tailored lipid-lowering strategies in patients with chronic kidney disease due to unique alterations in lipid metabolism and differing efficacy and safety profiles.
Synapse has enriched 10 related papers. Consider them for comparative context: